Brought to you by 
Cantabio licenses U. Cambridge's tau protein IP for AD
08 Jun 2022
Executive Summary
To develop potential Alzheimer's disease (AD) therapeutics, Cantabio Pharmaceuticals Inc. (formerly Gardedam Therapeutics) licensed a therapeutic program involving the tau protein from the University of Cambridge through its tech transfer arm Cambridge Enterprise Ltd.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cantabio licenses U. Cambridge's tau protein IP for AD
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice